CareDx Reports Strong Q2 Earnings with Revenue Growth of 52%
CareDx (NASDAQ:CDNA) reported a significant revenue increase in the second quarter, rising 52% year-over-year to $132 million. The growth was primarily driven by a 61% surge in testing-services revenue and an overall rise in test volume to 58,000 tests. Adjusted EBITDA reached $25 million for the period, while GAAP net income included a substantial gain of $113 million from selling its lab products business. The company raised its full-year 2026 revenue guidance to between $490 million and $500 million. This revised forecast incorporates contributions from NavDx, which was acquired in July, as well as the removal of a previously anticipated Medicare coverage impact. CareDx is also advancing key products like AlloHeme and HistoMap toward future launches. Management highlighted that finalized Medicare coverage supports transplant surveillance testing and could potentially pave the way for new product adoption.
Tickers: $CDNA
Topics: acquisition_integration adjusted_ebitda financial_results revenue_growth